NCT05137730View on ClinicalTrials.gov

A Study of Relative Bioavailability of a New Formulation Compared With the Approved Formulation of rhPTH [1-84] and to Find Out Dose Linearity of the New Formulation in Healthy Adults

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 29, 2021

Primary Completion Date

April 15, 2022

Study Completion Date

April 15, 2022

Conditions

Healthy Volunteers

Interventions

DRUG

rhPTH(1-84)

Participants in both part I and part II of the study will receive a single SC injection of rhPTH(1-84) depending upon the treatment sequence allocation on Day 1 of each treatment period.

Trial Locations (1)

85283

Celerion, Tempe